- 10x Genomics is a global life sciences technology company at the forefront of single-cell sequencing and spatial/temporal genomics.
- The company has a strong financial position and expects +66% revenue growth in 2021, but the stock trades at an expensive 61.92 P/S.
- Management predicts $480-$500M in revenue in 2021, short of the analyst average $495M. Missed forward guidance resulted in a <20% correction despite a 59.75% positive surprise on earnings.
- The author labels 10x Genomics a Hold. Post-COVID tailwinds hold numerous opportunities for growth but there is a serious premium to be paid.
For further details see:
10x Genomics: Expensive And Poised For Growth Post-COVID